Home Newsletters Pulmonary Cell News US FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting...

US FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer

By
Justin.choi
-
0
Foundation Medicine, Inc. announced it has received approval from the US FDA for FoundationOne®CDx to be used as a companion diagnostic to identify patients with NSCLC.
[Foundation Medicine, Inc.]
6445212 BBBBBBBB items 1 apa 0 default asc 1 173021 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
Press Release

RELATED ARTICLES

Exit mobile version